DZ2741A1 - Composés nouveaux antagonistes des récepteurs de vitronectine procédé pour leur préparation et compositions. - Google Patents
Composés nouveaux antagonistes des récepteurs de vitronectine procédé pour leur préparation et compositions.Info
- Publication number
- DZ2741A1 DZ2741A1 DZ990042A DZ990042A DZ2741A1 DZ 2741 A1 DZ2741 A1 DZ 2741A1 DZ 990042 A DZ990042 A DZ 990042A DZ 990042 A DZ990042 A DZ 990042A DZ 2741 A1 DZ2741 A1 DZ 2741A1
- Authority
- DZ
- Algeria
- Prior art keywords
- compositions
- preparation
- receptor antagonists
- new compounds
- vitronectin receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7761098P | 1998-03-10 | 1998-03-10 | |
US9606398P | 1998-08-11 | 1998-08-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
DZ2741A1 true DZ2741A1 (fr) | 2003-09-08 |
Family
ID=26759473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DZ990042A DZ2741A1 (fr) | 1998-03-10 | 1999-03-10 | Composés nouveaux antagonistes des récepteurs de vitronectine procédé pour leur préparation et compositions. |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1061921A4 (xx) |
JP (1) | JP2002506033A (xx) |
KR (1) | KR20010041812A (xx) |
CN (1) | CN1299282A (xx) |
AP (1) | AP2000001898A0 (xx) |
AR (1) | AR015241A1 (xx) |
AU (1) | AU758498B2 (xx) |
BG (1) | BG104824A (xx) |
BR (1) | BR9908636A (xx) |
CA (1) | CA2323208A1 (xx) |
CO (1) | CO5080762A1 (xx) |
DZ (1) | DZ2741A1 (xx) |
EA (1) | EA200000921A1 (xx) |
HU (1) | HUP0101143A3 (xx) |
ID (1) | ID26223A (xx) |
IL (1) | IL138245A0 (xx) |
NO (1) | NO20004503L (xx) |
OA (1) | OA12189A (xx) |
PE (1) | PE20000323A1 (xx) |
PL (1) | PL342881A1 (xx) |
SK (1) | SK13292000A3 (xx) |
TR (1) | TR200002625T2 (xx) |
UY (2) | UY25421A1 (xx) |
WO (1) | WO1999045927A1 (xx) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19939981A1 (de) * | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Neue Inhibitoren des Integrins alphavß3 |
DE19939980A1 (de) * | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Inhibitoren des Integrins alphavbeta¶3¶ |
EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
US6881736B1 (en) | 1999-09-07 | 2005-04-19 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
US6448278B2 (en) | 1999-12-23 | 2002-09-10 | Pfizer Inc. | Procollagen C-proteinase inhibitors |
GB9930570D0 (en) * | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
FR2808798A1 (fr) * | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | Nouveaux derives antagonistes du recepteur de la vitronectine |
UY26780A1 (es) | 2000-06-15 | 2002-01-31 | Pharmacia Corp | Cicloalquil avb3 antagonistas |
US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
US6645993B2 (en) | 2001-03-30 | 2003-11-11 | Warner-Lambert Company | 3-heterocyclylpropanohydroxamic acid PCP inhibitors |
US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
WO2005049589A2 (en) * | 2003-10-14 | 2005-06-02 | Cadila Healthcare Limited | Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases |
KR101150077B1 (ko) * | 2004-03-05 | 2012-06-01 | 다이쇼 세이야꾸 가부시끼가이샤 | 티아졸 유도체 |
UA87854C2 (xx) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-бензил)-2-фенілбутанаміди як модулятори рецептора андрогену$n-(2-бензил)-2-фенилбутанамиды как модуляторы рецептора андрогена |
US7262210B2 (en) | 2005-04-20 | 2007-08-28 | Janssen Pharmaceutica N.V. | Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls |
AU2014312756B2 (en) * | 2013-08-29 | 2018-11-22 | Kyoto Pharmaceutical Industries, Ltd. | Novel aromatic compound and use thereof |
PL3050878T3 (pl) | 2013-09-24 | 2022-01-24 | Fujifilm Corporation | Zawierający atom azotu związek lub jego sól, lub ich kompleks z metalem |
MX2016015467A (es) | 2014-05-30 | 2017-03-23 | Pfizer | Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos. |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0895475A4 (en) * | 1995-12-29 | 2000-08-23 | Smithkline Beecham Corp | VITRONECTIN RECEPTOR ANTAGONISTS |
IL125030A0 (en) * | 1995-12-29 | 1999-01-26 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
-
1999
- 1999-03-10 CN CN99805833A patent/CN1299282A/zh active Pending
- 1999-03-10 SK SK1329-2000A patent/SK13292000A3/sk unknown
- 1999-03-10 AU AU29033/99A patent/AU758498B2/en not_active Ceased
- 1999-03-10 AP APAP/P/2000/001898A patent/AP2000001898A0/en unknown
- 1999-03-10 PL PL99342881A patent/PL342881A1/xx unknown
- 1999-03-10 IL IL13824599A patent/IL138245A0/xx unknown
- 1999-03-10 EP EP99909952A patent/EP1061921A4/en not_active Withdrawn
- 1999-03-10 WO PCT/US1999/005232 patent/WO1999045927A1/en not_active Application Discontinuation
- 1999-03-10 CO CO99014712A patent/CO5080762A1/es unknown
- 1999-03-10 KR KR1020007010091A patent/KR20010041812A/ko not_active Application Discontinuation
- 1999-03-10 EA EA200000921A patent/EA200000921A1/ru unknown
- 1999-03-10 CA CA002323208A patent/CA2323208A1/en not_active Abandoned
- 1999-03-10 DZ DZ990042A patent/DZ2741A1/xx active
- 1999-03-10 HU HU0101143A patent/HUP0101143A3/hu unknown
- 1999-03-10 PE PE1999000188A patent/PE20000323A1/es not_active Application Discontinuation
- 1999-03-10 TR TR2000/02625T patent/TR200002625T2/xx unknown
- 1999-03-10 UY UY25421A patent/UY25421A1/es unknown
- 1999-03-10 OA OA00000248A patent/OA12189A/en unknown
- 1999-03-10 BR BR9908636-0A patent/BR9908636A/pt not_active Application Discontinuation
- 1999-03-10 AR ARP990101019A patent/AR015241A1/es not_active Application Discontinuation
- 1999-03-10 ID IDW20001737A patent/ID26223A/id unknown
- 1999-03-10 JP JP2000535342A patent/JP2002506033A/ja not_active Withdrawn
- 1999-05-19 UY UY25519A patent/UY25519A1/es unknown
-
2000
- 2000-09-08 NO NO20004503A patent/NO20004503L/no unknown
- 2000-10-03 BG BG104824A patent/BG104824A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
PE20000323A1 (es) | 2000-05-24 |
EA200000921A1 (ru) | 2001-04-23 |
HUP0101143A2 (hu) | 2001-08-28 |
BR9908636A (pt) | 2002-01-08 |
ID26223A (id) | 2000-12-07 |
AU2903399A (en) | 1999-09-27 |
EP1061921A1 (en) | 2000-12-27 |
TR200002625T2 (tr) | 2000-12-21 |
UY25519A1 (es) | 1999-12-13 |
JP2002506033A (ja) | 2002-02-26 |
OA12189A (en) | 2006-05-09 |
KR20010041812A (ko) | 2001-05-25 |
UY25421A1 (es) | 2001-07-31 |
SK13292000A3 (sk) | 2001-06-11 |
PL342881A1 (en) | 2001-07-16 |
EP1061921A4 (en) | 2005-03-30 |
WO1999045927A1 (en) | 1999-09-16 |
AR015241A1 (es) | 2001-04-18 |
CA2323208A1 (en) | 1999-09-16 |
NO20004503L (no) | 2000-10-10 |
IL138245A0 (en) | 2001-10-31 |
NO20004503D0 (no) | 2000-09-08 |
HUP0101143A3 (en) | 2002-12-28 |
AU758498B2 (en) | 2003-03-20 |
CN1299282A (zh) | 2001-06-13 |
BG104824A (en) | 2001-05-31 |
AP2000001898A0 (en) | 2000-09-30 |
CO5080762A1 (es) | 2001-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DZ2741A1 (fr) | Composés nouveaux antagonistes des récepteurs de vitronectine procédé pour leur préparation et compositions. | |
DZ2729A1 (fr) | Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant. | |
DZ3052A1 (fr) | Composés nouveaux inhibiteurs de métalloprotéases,procédé pour leur préparation et compositions pha rmaceutiques les contenant. | |
DZ2962A1 (fr) | Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant. | |
DZ2440A1 (fr) | Atropisomères de 3-aryl-4(3h)-quinazolinones procédé pour leur préparation et compositions les contenant. | |
CY2537B1 (fr) | Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant | |
DZ2753A1 (fr) | Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant. | |
DZ3038A1 (fr) | Modulateurs nouveaux des récepteurs de glucocorticoïdes, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2963A1 (fr) | Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2891A1 (fr) | Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2826A1 (fr) | Formulaons intranasales de mésylate de sildénafil et procédé pour leur préparation. | |
DZ2128A1 (fr) | Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
MA26659A1 (fr) | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. | |
DZ2465A1 (fr) | Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions les contenant. | |
DZ2217A1 (fr) | Dérivés d'imidazole substitués, procédé pour leur préparation et compositions les contenant. | |
DZ2866A1 (fr) | 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2360A1 (fr) | Dérivés de pyrazole procédé pour leur préparation et compositions les contenant | |
DZ3016A1 (fr) | Composés nouveaux inhibiteurs de réabsorption de monoamines, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2890A1 (fr) | 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2889A1 (fr) | 4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant. | |
DZ2394A1 (fr) | Dérivés de quinoléine et dérivés de quinazoline nouveax procédé pour leur préparation et compositions pharmaceutiques les contenant | |
DZ2923A1 (fr) | Formulations pharmaceutiques d'inhibiteurs de pde-5 de gmpc à libération contrôlée, et procédé pour leur préparation. | |
DZ2777A1 (fr) | Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ3045A1 (fr) | Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2751A1 (fr) | Composés calciolytiques nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |